VivoSim Labs (VIVS) Other Accumulated Expenses (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Other Accumulated Expenses of $36000.0 for Q1 2026, down 38.98% year-over-year from $59000.0 in Q1 2025, and up 125.0% quarter-over-quarter from $16000.0 in Q4 2025.
VivoSim Labs (VIVS) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
VivoSim Labs' Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 38.98% year-over-year to $36000.0; the TTM figure through Mar 2026 stood at $36000.0 (down 38.98% YoY), while the FY2026 annual figure was $36000.0, down 38.98% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $36000.0, up from $16000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $334000.0 in Q3 2023, with the low at $9000.0 in Q3 2025.
- The 5-year median for Other Accumulated Expenses is $59000.0 (2025), against an average of $89923.1.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 113.04% in 2024, then plunged 91.96% in 2025.
- VivoSim Labs' Other Accumulated Expenses stood at $28000.0 in 2022, then soared by 582.14% to $191000.0 in 2023, then climbed by 4.19% to $199000.0 in 2024, then slumped by 91.96% to $16000.0 in 2025, then soared by 125.0% to $36000.0 in 2026.
- Business Quant data shows VIVS's Other Accumulated Expenses at $36000.0 in Q1 2026, $16000.0 in Q4 2025, and $9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 199,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 191,000.00 |
| Sep 30, 2023 | 334,000.00 |
| Mar 31, 2023 | 46,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Mar 31, 2021 | 31,000.00 |
| Mar 31, 2020 | 21,000.00 |
| Mar 31, 2019 | 237,000.00 |
| Mar 31, 2018 | 507,000.00 |
| Mar 31, 2017 | 211,000.00 |
| Mar 31, 2016 | 61,000.00 |